bioRxivMicrobiology
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
S. Iketani, F. Forouhar, H. Liu, S. J. Hong, F.-Y. Lin, M. S. Nair, A. Zask, Y. Huang, L. Xing, B. R. Stockwell, A. Chavez, D. D. Ho
Abstract
We report the identification of three structurally diverse compounds - compound 4, GC376, and MAC-5576 - as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development of highly potent non-covalent inhibitors of SARS-CoV-2 3CLpro
- Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19
Yuto Unoh, Keiichiro Hirai, … Yuki Tachibana·Journal of Medicinal ChemistryPeer-reviewed·Jul 5, 2025
- Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening
- Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro
- Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
Y. Unoh, S. Uehara, … Y. Tachibana·bioRxiv·Jan 26, 2022
- Discovery of Potent Pyrazoline-Based Covalent SARS-CoV-2 Main Protease Inhibitors
P. Moon, L. Boike, … D. K. Nomura·bioRxiv·Mar 5, 2022